Director, Chemistry
CurrentDeveloped novel antibody-oligonucleotide conjugates to treat rare muscle disorders. Developed analytical methods to characterize antibody-oligonucleotide conjugate purity and stability.Scaled antibody-siRNA conjugate production and purification from microgram scale for HTS to multi-gram scale for NHP studies.Managed manufacturing of oligonucleotide and antibody oligonucleotide conjugates, including technology transfer, process development, scheduling logistics, batch record review, change controls, review of validation protocols, and development of specifications.